Drug intelligence / Profile preview

Hepatitis A vaccine (adult)

Development stage: Unknown
Lead developer: KEYMEN
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Hepatitis A vaccine (adult) is an inactivated virus vaccine developed and distributed by Keymen İlaç, a pharmaceutical subsidiary of Alagöz Holding. It is indicated for the active immunization of adults against infection caused by the Hepatitis A virus (HAV). The vaccine works by stimulating the immune system to produce neutralizing antibodies against HAV, thereby providing long-term protection. Keymen İlaç is a prominent vaccine supplier in Turkey, and this product is part of its portfolio of approved vaccines used in national public health programs. It is typically administered via intramuscular injection.

Brand names: Erişkin Tip Hepatit A Aşısı
Other names: Adult Hepatitis A Vaccine

Beyond the preview

Go deeper on Hepatitis A vaccine (adult).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis A vaccine (adult).

Explore the full profile